ASXL1 and myelodysplastic syndrome: Morphologic and molecular markers by NGS help to distinguish PMF from other MPNs, MDS, and reactive processes, while molecular markers (e.g., ASXL1, SRSF2, TP53) can additionally guide individualized therapy.